[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349081-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349081-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","in-vitro-evaluation-of-parp1-inhibitor-olaparib-cyanine-dye-conjugate-for-the-treatment-of-glioblastoma-proof-of-concept-in-vitro-cellular-activity","In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma - Proof of Concept In Vitro Cellular Activity","","Inhibition of DNA damage repair is a widely used strategy to drive cancer cell death, but delivering effective agents to brain tumours has remained difficult because compounds must satisfy stringent structural requirements to cross the blood–brain barrier (BBB). This study demonstrates proof of concept for the in vitro cellular activity of a PARP1 inhibitor, olaparib, conjugated to a BBB-crossing heptamethine cyanine dye. The work provides evidence of cellular uptake and PARP1 inhibition by the conjugate, supporting improved potency.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/in-vitro-evaluation-of-parp1-inhibitor-olaparib-cyanine-dye-conjugate-for-the-treatment-of-glioblastoma-proof-of-concept-in-vitro-cellular-activity/349081/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/in-vitro-evaluation-of-parp1-inhibitor-olaparib-cyanine-dye-conjugate-for-the-treatment-of-glioblastoma-proof-of-concept-in-vitro-cellular-activity/349081.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of conjugating olaparib with a heptamethine cyanine dye?","Question",{"text":63,"@type":64},"The conjugate is designed to improve BBB-associated delivery while enabling PARP1 inhibition, supporting stronger in vitro cellular effects against glioblastoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence does the study provide for the conjugate’s activity in cells?",{"text":68,"@type":64},"It reports evidence for cellular uptake of the conjugate and inhibition of PARP1, which together relate to the observed improvement in potency.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are BBB and BTB considered critical in glioblastoma drug development?",{"text":72,"@type":64},"The BBB/BTB restrict delivery of many therapeutic agents, and efflux mechanisms can reduce drug bioavailability in tumour tissue, limiting efficacy despite promising drug mechanisms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349081,1790187401,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":22,"preview_urls":144},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","ChemMedChem  \nRESEARCH ARTICLE   \nIn Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma  \nCarina Dumo1,2,3 | Faheem4  | Peter J. Choi1,4 | Nicholas J. Pederson5 | Yuge Liu1 | Mike Dragunow2,3 | Thomas I-H. Park2,3 | Katharine L. Diehl5 | Jiney Jose1,4   \n1Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand | 2Department of Pharmacology & The Centre for Brain Research, University of Auckland, Auckland, New Zealand | 3Neurosurgical Research Unit, The Centre for Brain Research, University of Auckland, Auckland, New Zealand | 4Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand | 5Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, USA  \nCorrespondence: Katharine L. Diehl ([k.diehl@utah.edu](k.diehl@utah.edu)) | Jiney Jose ([j.jose@auckland.ac.nz](j.jose@auckland.ac.nz))  \nReceived: 14 February 2026 | Revised: 8 April 2026 | Accepted: 10 April 2026  \nKeywords: glioblastoma | heptamethine cyanine dyes | olaparib | PARP inhibition  \nABSTRACT  \nInhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain barrier (BBB) . This study presents the proof of concept in vitro cellular activity of PARP1 (Poly(ADP-ribose) polymerase 1) enzyme inhibitor olaparib conjugated with a known BBB-crossing heptamethine cyanine dye. We also present evidence for cellular uptake and PARP1 inhibition by the conjugate, which contributes to the observed improvement in potency.  \n1 | Background  \nGlioblastoma (GBM), despite significant clinical advancements, remains a near-fatal diagnosis for patients, leading to immense emotional and financial strain on their families. The standard of care for GBM patients is similar in most countries, with survival rates stagnating at 􀀁 15 months for over 30 years since the approval of Temozolomide (TMZ) as the primary chemotherapy treatment. Despite years of research to identify effective therapies for GBM, treatments other than TMZ have not shown substantial benefits for the patient population. Drugs such as platinum-based agents [1], nitrosoureas [2], and more recently, bevacizumab [3] have been effective in some patient populations, but none of them provide a meaningful extension of overall survival compared to TMZ alone. Tumour-treating fields (TTF), when combined with TMZ therapy, have shown to extend overall survival by 􀀁 3 months [4] . TTF is not available in all countries, and even if it is made available, it may not be viable for all patients due to the high cost of treatment for the marginal  \nincrement in survival that the treatment provides [5] . The modest survival benefit afforded by TTF also makes it difficult for national health agencies to subsidise the treatment.  \nA shift in how we approach GBM drug development is critical, especially given the disease’s unique features and differences from other cancers. The aggressive and infiltrative nature of GBM makes cancer therapies successful in treating other cancers, mostly redundant when applied to GBM [6, 7] . Surgery followed by radiation to remove residual tumour left behind, followed by chemotherapy, cannot eliminate all cancer cells, eventually leading to recurrence and progression of disease, leading to untimely death. Therefore, treatments tailored to take into account the exclusive features of the disease are urgently required. Medicine development also has to take into account the presence of the blood–brain barrier (BBB) and the blood–tumour barrier (BTB), which restricts the delivery of many therapeutic agents. Most chemotherapies are not designed to cross these barriers, thus negati","cbCaimXw9B3rCY78","https://ap.wps.com/l/cbCaimXw9B3rCY78","pdf",912396,"English","# Background\n## Blood–brain barrier and delivery barriers\n## Current standard of care and limitations\n# In vitro proof of concept (PARP1 inhibition and uptake)","[{\"question\":\"What is the main purpose of conjugating olaparib with a heptamethine cyanine dye?\",\"answer\":\"The conjugate is designed to improve BBB-associated delivery while enabling PARP1 inhibition, supporting stronger in vitro cellular effects against glioblastoma.\"},{\"question\":\"What evidence does the study provide for the conjugate’s activity in cells?\",\"answer\":\"It reports evidence for cellular uptake of the conjugate and inhibition of PARP1, which together relate to the observed improvement in potency.\"},{\"question\":\"Why are BBB and BTB considered critical in glioblastoma drug development?\",\"answer\":\"The BBB/BTB restrict delivery of many therapeutic agents, and efflux mechanisms can reduce drug bioavailability in tumour tissue, limiting efficacy despite promising drug mechanisms.\"}]","In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma - Proof of Concept In Vitro Cellular Activity | PDF",1790081531,[145],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/2d574ac49faac3c321b1f3b700f76db9.webp",983,1291]